Literature DB >> 10451036

Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway.

H Olsen1, T Klemetsrud, H P Stokke, S Tretli, A Westheim.   

Abstract

The objective of this study was to determine the frequency and profile of adverse reactions to antihypertensive drugs in an unselected group of drug-treated hypertensive patients. A questionnaire-based survey was carried out among 2586 drug-treated hypertensive patients who attended a general practitioner for clinical control. Adverse drug reactions reported spontaneously, upon general inquiry, upon specific questioning and as evaluated by a physician were used as the main outcome measures. The study shows that the percentage of patients who reported adverse drug reactions spontaneously, upon general inquiry and upon specific questioning were 16%, 24% and 62% respectively. Users of diuretics reported the lowest frequency of adverse reactions, whereas users of beta-blockers reported the highest frequency. In 7% of the patients, the adverse drug reactions were of such a nature that the physicians considered discontinuing the treatment. As a conclusion, the reported frequency of adverse drug reactions in antihypertensive treatment is high, but with significant differences between the various drug groups. Monotherapy is connected with far fewer adverse drug reactions than combination therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10451036     DOI: 10.1080/080370599438266

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  23 in total

Review 1.  Managing comorbidities in patients at the end of life.

Authors:  James Stevenson; Amy P Abernethy; Cathy Miller; David C Currow
Journal:  BMJ       Date:  2004-10-16

2.  On the criteria used for assessing the risk of bias in randomized trials included in systematic reviews and meta-analyses addressing adverse effects.

Authors:  Stefanos Bonovas; Theodore Lytras; Georgios Nikolopoulos
Journal:  Eur J Epidemiol       Date:  2015-03-15       Impact factor: 8.082

3.  Somatosensory Amplification Is a Predictor of Self-Reported Side Effects in the Treatment of Primary Hypertension: a Pilot Study.

Authors:  Bettina K Doering; Judit Szécsi; György Bárdos; Ferenc Köteles
Journal:  Int J Behav Med       Date:  2016-06

4.  The timeliness of patients reporting the side effects of chemotherapy.

Authors:  Ian Olver; Mariko Carey; Allison Boyes; Alix Hall; Natasha Noble; Jamie Bryant; Justin Walsh; Rob Sanson-Fisher
Journal:  Support Care Cancer       Date:  2018-05-03       Impact factor: 3.603

5.  Hypertension in women: latest findings and clinical implications.

Authors:  Helga Gudmundsdottir; Aud Høieggen; Aud Stenehjem; Bård Waldum; Ingrid Os
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

6.  A pharmacovigilance study of antihypertensive medicines at a South delhi hospital.

Authors:  A Hussain; M Aqil; M S Alam; M R Khan; P Kapur; K K Pillai
Journal:  Indian J Pharm Sci       Date:  2009-05       Impact factor: 0.975

7.  Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting.

Authors:  Carla B C Gonçalves; Leila B Moreira; Miguel Gus; Flávio D Fuchs
Journal:  Eur J Clin Pharmacol       Date:  2007-08-11       Impact factor: 2.953

8.  Aged garlic extract reduces blood pressure in hypertensives: a dose-response trial.

Authors:  K Ried; O R Frank; N P Stocks
Journal:  Eur J Clin Nutr       Date:  2012-11-21       Impact factor: 4.016

9.  Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK.

Authors:  Tom Walley; Andy K Duggan; Alan R Haycox; Christie J Niziol
Journal:  J R Soc Med       Date:  2003-11       Impact factor: 18.000

10.  Monitoring of adverse drug reactions associated with antihypertensive medicines at a university teaching hospital in New Delhi.

Authors:  Fowad Khurshid; Mohammed Aqil; Mohammad Shamshir Alam; Prem Kapur; Krishna K Pillai
Journal:  Daru       Date:  2012-09-10       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.